ClinicalTrials.gg
CompletedNCT06561841Updated Jun 29, 2025

A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria(PNH)

A Phase 2 interventional study of HSK39297 in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-29.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 21 open to participants now, 29 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Enrollment
21st of 47
47 · median 40
Started
2024
with 11 others
Phase 2
13 of 51
4 open now
Registered
23rd of 51
by date
Lead sponsor
5 of 51
Haisco Pharmaceutical Group Co., Ltd.

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 21st largest by enrollment of the 47 interventional ones that give a count, is one of 12 that started in 2024, is one of 13 in phase 2, and was the 23rd registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

21 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label phase 2 study. Adult Patients with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy were included. Subjects were treated with HSK39297 for 24 weeks.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants ≥ 18 years of age;
  2. Diagnosis of PNH based on flow cytometry with clone size > 10% by granulocytes;
  3. Have not received complement inhibitor treatment;
  4. Blood lactate dehydrogenase(LDH) values > 1.5 × (ULN) ;
  5. level \< 100 g/L during the screening period.

Exclusion criteria

Exclusion Criteria:

  1. Hereditary or acquired complement deficiency;
  2. Active primary or secondary immunodeficiency;
  3. History of splenectomy, bone marrow/ hematopoietic stem cell or solid organ transplants;
  4. History of recurrent invasive infections caused by encapsulated organisms( e.g. meningococcus or pneumococcus) or Mycobacterium tuberculosis;
  5. Patients with laboratory evidence of bone marrow failure (reticulocytes \< 100x10\^9/L, or \< 30x10\^9/L or neutrophils \< 0.5x10\^9/L) ;
  6. Active systemic infection within 2 weeks prior to study drug administration;
  7. History of serious comorbidities that have been determined to be unsuitable for participation in the study.
  8. Pregnant or Lactating women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Drug: HSK39297

  • Experimental
    Treatment group B

    Drug: HSK39297

  • Experimental
    Treatment group C

    Drug: HSK39297

Interventions

  • HSK39297 tablets for 24 weeks

06

What researchers measure

Primary outcomes

  1. Proportion of participants with increase in hemoglobin levels from baseline of ≥20 g/L in the absence of red blood cell transfusions

    Time frame: Baseline, 24 weeks

Secondary outcomes

  1. Proportion of participants with at least 60% reduction in LDH compared to baseline or LDH below the upper limit of normal

    Time frame: Baseline, 24 weeks

  2. Change from baseline in hemoglobin

    Time frame: Baseline, 24 weeks

  3. Change from baseline in reticulocyte count

    Time frame: Baseline, 24 weeks

  4. Change from baseline in LDH

    Time frame: Baseline, 24 weeks

  5. Change from baseline in Indirect bilirubin

    Time frame: Baseline, 24 weeks

  6. Change from baseline in free hemoglobin

    Time frame: Baseline, 24 weeks

  7. Proportion of participants without requiring red blood cells (RBC) transfusions

    Time frame: From week 4 to week 24

  8. Change in the average number of RBC transfused per week

    Time frame: From week 4 to week 24

  9. Change from baseline in PNH RBC clone size

    Time frame: Baseline, 24 weeks

  10. Change from baseline in C3 fragment deposition on PNH RBC

    Time frame: Baseline, 24 weeks

  11. Change from baseline in FACIT-Fatigue score

    Time frame: Baseline, 24 weeks

  12. Incidence and severity of adverse events

    Time frame: 28 weeks

07

Study locations

1 site
  • The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210029, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Apr 2025, 8 months.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 8 months is below that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2024
First posted
Aug 20, 2024
StartActual
Jul 17, 2024
Primary completionActual
Apr 2, 2025
CompletionActual
Apr 2, 2025
Last update
Jun 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06561841
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Jul 17, 2024
Primary completion
Apr 2, 2025
Completion
Apr 2, 2025
Last update
Jun 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK39297

Start the discussion